FDA Accepts BLA for Afami-Cel for Priority Review as Treatment of Advanced Synovial Sarcoma
Afami-cel had engineered t-cell receptor T-cells target MAGE-A4+ tumors, which are highly expressed in synovial sarcoma with HLA-A*02.
Dennis Williams Connective Tissue Oncology Society Eastern Cooperative Oncology Group Stage Development At Adaptimmune Therapeutics Adaptimmune Therapeutics Prescription Drug User Fee Act
Source: pharmacytimes.com